Investigation of Serum Levels and Activity of Matrix Metalloproteinases 2 and 9 (MMP2, 9) in Opioid and Methamphetamine-Dependent Patients

  • Khadijeh Najafi Pharmacy Student Research Committee, School of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran.
  • Daniel Elieh Ali Komi Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. AND Department of Immunology, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Habibolah Khazaie Sleep Disorders Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran. AND Substance Abuse Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
  • Ali Moini Department of Internal Medicine, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran.
  • Asad Vaisi-Raygani Department of Biochemistry, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
  • Hamid Reza Ahmadi Substance Abuse Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
  • Mohammad Rasoul Ghadami Sleep Disorders Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
  • Amir Kiani Department of Pharmacology and Toxicology, School of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran. AND Regenerative Medicine Research Center (RMRC), Kermanshah University of Medical Sciences, Kermanshah, Iran.
Keywords: Drug dependence, Matrix metalloproteinase, Morphine, Methamphetamine

Abstract

Matrix metalloproteinases (MMPs) are a group of zinc-dependent proteolytic enzymes that play a role in extracellular matrix (mainly collagen) degradation and remodeling. MMPs are not only causes of the increase rewarding effects of drugs, but also act as pro-addictive agents. In this research, 22 morphine and 20 methamphetamine-dependent patients included and their serum levels and activity of MMP2 and 9 were assessed by ELISA and gelatin zymography and compared with those of 23 healthy individuals as a control group. Our findings showed a significant increase in serum levels and activity of MMP-2 in opium and methamphetamine groups in comparison with the control group. Moreover, unlike MMP-2, serum levels and activity of MMP-9 in both case groups found to be decreased. This study showed that long-term abuse of opium and methamphetamine changes the activity and serum levels of MMP9 and MMP2. The effects of methamphetamines and opium are associated with an increase in extracellular dopamine levels in the brain, achieved by facilitating the release of dopamine from pre-synaptic nerves. Our findings showed that serum levels and activities of MMP-9 and MMP-2 could be considered as alternative valuable biomarkers from those investigated of pro-addictive or anti-addictive factors in dependent patients.

References

NAJAFI K, AHMADI S, RAHPEYMA M, KHAZAIE H, VAISI-RAYGANI A, MOINI A. et al. Study of Serum Malondialdehyde Level in Opioid and Methamphetamine Dependent Patients, Acta medica Iranica 2017; 55: 616-620.

HENRY. Effect of methamphetamine dependence on heart rate variability, Addiction biology 2012; 17: 648-658.

MIZOGUCHI H, YAMADA K, NABESHIMA T. Neuropsychotoxicity of abused drugs: involvement of matrix metalloproteinase-2 and -9 and tissue inhibitor of matrix metalloproteinase-2 in methamphetamine-induced behavioral sensitization and reward in rodents, Journal of pharmacological sciences 2008; 106: 9-14.

LIU C, HUA Z, BAI Y. Classification of Opium by UPLC-Q-TOF Analysis of Principal and Minor Alkaloids, Journal of forensic sciences 2016; 61: 1615-1621.

STEIDL S, WASSERMAN D. I, BLAHA C. D, YEOMANS J. S. Opioid-induced rewards, locomotion, and dopamine activation: A proposed model for control by mesopontine and rostromedial tegmental neurons, Neuroscience and biobehavioral reviews 2017; 83: 72-82.

GARCIA-PEREZ D, NUNEZ C, LAORDEN M. L, MILANES M. V. Regulation of dopaminergic markers expression in response to acute and chronic morphine and to morphine withdrawal, Addiction biology 2016; 21: 374-386.

YAMADA K. Pro-addictive and anti-addictive factors for drug dependence, Nagoya journal of medical science 2008; 70: 67-72.

SMIGIEL K. S, PARKS W. C. Matrix Metalloproteinases and Leukocyte Activation, Progress in molecular biology and translational science 2017; 147: 167-195.

NISSINEN L, KAHARI V. M. Matrix metalloproteinases in inflammation, Biochimica et biophysica acta 2014; 1840: 2571-2580.

SHARIFTABRIZI A, NIFLI A. P, ANSARI M, SAADAT F, EBRAHIMKHANI M. R, ALIZADEH N. et al. Matrix metalloproteinase 2 secretion in WEHI 164 fibrosarcoma cells is nitric oxide-related and modified by morphine, European journal of pharmacology 2006; 530: 33-39.

FRANCO C, PATRICIA H. R, TIMO S, CLAUDIA B, MARCELA H. Matrix Metalloproteinases as Regulators of Periodontal Inflammation, International journal of molecular sciences 2017; 18.

JAVAID M. A, ABDALLAH M. N, AHMED A. S, SHEIKH Z. Matrix metalloproteinases and their pathological upregulation in multiple sclerosis: an overview, Acta neurologica Belgica 2013; 113: 381-390.

VANDOOREN J, VAN DEN STEEN P. E, OPDENAKKER G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade, Critical reviews in biochemistry and molecular biology 2013; 48: 222-272.

ELIEH-ALI-KOMI D, CAO Y. Role of Mast Cells in the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis, Clinical reviews in allergy & immunology 2017; 52: 436-445.

ELIEH ALI KOMI D, GRAUWET K. Role of Mast Cells in Regulation of T Cell Responses in Experimental and Clinical Settings, Clinical reviews in allergy & immunology 2017.

ZHANG C, GONG W, LIU H, GUO Z, GE S. Inhibition of matrix metalloproteinase-9 with low-dose doxycycline reduces acute lung injury induced by cardiopulmonary bypass, International journal of clinical and experimental medicine 2014; 7: 4975-4982.

MIZOGUCHI H, YAMADA K, NIWA M, MOURI A, MIZUNO T, NODA Y. et al. Reduction of methamphetamine-induced sensitization and reward in matrix metalloproteinase-2 and -9-deficient mice, Journal of neurochemistry 2007; 100: 1579-1588.

MARTINS T, BAPTISTA S, GONCALVES J, LEAL E, MILHAZES N, BORGES F. et al. Methamphetamine transiently increases the blood-brain barrier permeability in the hippocampus: role of tight junction proteins and matrix metalloproteinase-9, Brain research 2011; 1411: 28-40.

HART C. L, HANEY M, FOLTIN R. W, FISCHMAN M. W. Effects of the NMDA antagonist memantine on human methamphetamine discrimination, Psychopharmacology 2002; 164: 376-384.

JOHNSON B. A, AIT-DAOUD N, WELLS L. T. Effects of isradipine, a dihydropyridine-class calcium channel antagonist, on D-methamphetamine-induced cognitive and physiological changes in humans, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2000; 22: 504-512.

VU T. H, WERB Z. Matrix metalloproteinases: effectors of development and normal physiology, Genes & development 2000; 14: 2123-2133.

Published
2018-12-25
How to Cite
1.
Najafi K, Elieh Ali Komi D, Khazaie H, Moini A, Vaisi-Raygani A, Ahmadi HR, Ghadami MR, Kiani A. Investigation of Serum Levels and Activity of Matrix Metalloproteinases 2 and 9 (MMP2, 9) in Opioid and Methamphetamine-Dependent Patients. Acta Med Iran. 56(9):559-562.
Section
Articles